Robbie Majzner

Title: Robbie Majzner: Innovator in Cell Surface Receptors

Introduction

Robbie Majzner is a prominent inventor based in Stanford, California. He has made significant contributions to the field of biotechnology, particularly in the development of cell surface receptors. With a total of 3 patents, his work focuses on innovative therapeutic approaches that have the potential to transform cancer treatment.

Latest Patents

One of Majzner's latest patents is titled "Regulatable cell surface receptors and related compositions and methods." This patent describes engineered cell surface receptors that include an extracellular binding domain, a transmembrane domain, an intracellular signaling domain, and a protease cleavage site. These receptors can be utilized in various therapeutic applications, including regulatable cell-based therapies. Another notable patent is "Therapeutic antigen binding proteins specific for CD93 and methods of use thereof." This patent provides antigen binding domain polypeptides specific for human CD93, which can be formatted as antibodies or chimeric antigen receptors. T cells that incorporate an anti-CD93 CAR are particularly useful in treating hematologic malignancies.

Career Highlights

Robbie Majzner is affiliated with Leland Stanford Junior University, where he conducts his research and development. His innovative work has garnered attention in the scientific community, contributing to advancements in cancer therapies.

Collaborations

Majzner has collaborated with notable researchers, including Crystal L. Mackall and Michelle Monje-Deisseroth. These collaborations have further enhanced the impact of his work in the field of biotechnology.

Conclusion

Robbie Majzner's contributions to the development of cell surface receptors and therapeutic approaches highlight his role as an influential inventor in the biotechnology sector. His patents reflect a commitment to advancing cancer treatment through innovative solutions.